Immunome (IMNM) Earnings Date, Estimates & Call Transcripts $7.40 +0.05 (+0.68%) Closing price 04:00 PM EasternExtended Trading$7.38 -0.02 (-0.20%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunome Earnings Summary Upcoming Earnings DateMay. 13Before Market OpensEstimatedConsensus EPS (Mar. 19) -$0.68 Actual EPS (Mar. 19) -$0.84 Missed By -$0.16 Actual Revenue (Mar. 19) $2.74MImmunome posted Q4 2024 earnings on March 19, 2025, reporting an EPS of -$0.84, which missed analysts' consensus estimates of -$0.68 by $0.16. Quarterly revenue was reported to be $2.74 million, below analysts' expectations of $3.07 million. With a trailing EPS of -$5.17, Immunome's earnings are expected to decrease next year, from ($2.21) to ($3.23) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Press Release (8-K) Annual Report (10-K)IMNM Upcoming EarningsImmunome's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportPowered by Get Immunome Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIMNM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IMNM Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Immunome Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.94-$0.51-$0.69Q2 20253-$1.02-$0.44-$0.69Q3 20253-$1.02-$0.45-$0.71Q4 20253-$1.07-$0.46-$0.75FY 202512-$4.05-$1.86-$2.84Q1 20261-$0.80-$0.80-$0.80Q2 20261-$0.81-$0.81-$0.81Q3 20261-$0.67-$0.67-$0.67Q4 20261-$0.62-$0.62-$0.62FY 20264($2.90)($2.90)($2.90) Remove Ads Immunome Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/13/2025(Estimated)-------3/19/2025Q4 2024-$0.68-$0.84 -$0.16-$1.28$3.07M$2.74M8/12/2024Q2 2024-$0.38-$0.49 -$0.11-$0.38$2.62M$2.36M5/14/2024Q1 2024-$0.80-$0.34+$0.46$1.83$4.00M$1.03M3/28/2024Q4 2023-$0.28-$0.54 -$0.26$3.14$3.40M$3.83M11/9/2023Q3 2023--$0.36 -$0.36-$0.36-$3.57M8/9/2023Q2 2023--$0.46 -$0.46-$0.46-$4.26M5/5/2023Q1 2023--$0.35 -$0.35-$0.35-$2.36M Immunome Earnings - Frequently Asked Questions When is Immunome's earnings date? Immunome has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based off last year's report dates. Learn more on IMNM's earnings history. Did Immunome beat their earnings estimates last quarter? In the previous quarter, Immunome (NASDAQ:IMNM) missed the analysts' consensus estimate of ($0.68) by $0.16 with a reported earnings per share (EPS) of ($0.84). Learn more on analysts' earnings estimate vs. IMNM's actual earnings. How much revenue does Immunome generate each year? Immunome (NASDAQ:IMNM) has a recorded annual revenue of $9.04 million. How much profit does Immunome generate each year? Immunome (NASDAQ:IMNM) has a recorded net income of -$106.81 million. IMNM has generated -$5.17 earnings per share over the last four quarters. What is Immunome's EPS forecast for next year? Immunome's earnings are expected to decrease from ($2.21) per share to ($3.23) per share in the next year. More Earnings Resources from MarketBeat Related Companies Mirum Pharmaceuticals Earnings Vericel Earnings Bausch Health Companies Earnings Biohaven Earnings Tarsus Pharmaceuticals Earnings Belite Bio Earnings NewAmsterdam Pharma Earnings Metsera Earnings Arcutis Biotherapeutics Earnings Recursion Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NASDAQ:IMNM) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.